Insider filing · VRTX
Jeffrey M Leiden sold $28.7M of Vertex Pharmaceuticals Incorporated (VRTX)
Executed Dec 3 2025, disclosed Dec 5 2025, 2 days later.
Value, as filed
$28.7M
63,781 sh across 12 lots
Executed
Dec 3 2025
the trade date, as filed
Disclosed
Dec 5 2025
2 days after the trade
Return, 21 sessionsiFrom the disclosed entry session; derived
–
purchases only
Returns are measured on stock purchases only.
The filer
JL
Jeffrey M Leiden
Executive Chairman
profile →
Jeffrey M Leiden (Executive Chairman) filed 3 Form 4 reports in the trailing twelve months (1 purchase, 2 sales), most often in Vertex Pharmaceuticals Incorporated (VRTX). Across 1 priced purchase filing, the average 21-session return was -14.4% from execution and +3.2% from disclosure (delay-adjusted; derived). The largest single filing was $32.3M of VRTX (73,252 sh across 4 lots, as filed), executed Nov 13 2025.
The name
VRTX
Vertex Pharmaceuticals Incorporated
VRTX · Healthcare · 91 filings in 24 months
ticker →
Healthcare · Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→Other filings by Jeffrey M Leiden in VRTX
VRTXSALE
Vertex Pharmaceuticals Incorporated
$32.3M73,252 sh across 4 lots
Exec Nov 13 2025
Filed Nov 17 2025 · 5:30 PM ET